7-hydroxyflumequine: metabolite of flumequine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 162938 |
| SCHEMBL ID | 9703131 |
| MeSH ID | M0121021 |
| Synonym |
|---|
| 9-fluoro-7-hydroxy-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid |
| 7-hydroxyflumequine |
| 61293-22-9 |
| 1h,5h-benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-7-hydroxy-5-methyl-1-oxo- |
| SCHEMBL9703131 |
| AKOS030242537 |
| 7-fluoro-10-hydroxy-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5(13),6,8-tetraene-3-carboxylic acid |
| AS-6138 |
| DTXSID80976779 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The elimination half-life during PE (3." | ( Effect of plasma exchange on flumequine pharmacokinetics: comparison with control kinetics. Dureux, JB; Gérard, A; Royer, RJ; Royer-Morrot, MJ; Schooneman, F; Zhiri, A, 1991) | 0.28 |
| "The pharmacokinetic properties of flumequine and its metabolite 7-hydroxyflumequine were determined in six healthy sheep after single intramuscular (i." | ( Pharmacokinetics of flumequine in sheep after intravenous and intramuscular administration: bioavailability and tissue residue studies. Chapel, AM; Delmas, JM; Gaudin, V; Sanders, P, 1997) | 0.54 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The multiple dosage regimen yielded antimicrobial levels in both plasma and urine that were several-fold higher than the levels required to inhibit the growth of susceptible bacteria." | ( Plasma and urine levels of flumequine and 7-hydroxyflumequine following single and multiple oral dosing. Funk, ML; Hansen, CS; Harrison, LI; Miller, HL; Ober, RE; Rohlfing, SR; Schuppan, D, 1985) | 0.53 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||